SNORA19: A Potential Drug Target and Biomarker (G641451)

Target Name: SNORA19

NCBI ID: G641451

SNORA19

Other Name(s): small nucleolar RNA, H/ACA box 19 | Small nucleolar RNA, H/ACA box 19 | ACA19

SNORA19: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA), also known as H/ACA box 19, is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. SNORA19 is a 24-nt RNA molecule that is predominantly expressed in the nucleolus, the protein manufacturing center of the cell. It is composed of a stem-loop and an tail region, which allows it to interact with various protein factors in the nucleolus.

The discovery of SNORA19 and its functions have the potential to revolutionize our understanding of gene regulation and the development of new drugs. While several studies have identified potential drug targets based on SNORA19, more research is needed to fully determine its role and to develop new treatments.

One of the primary functions of SNORA19 is to interact with the protein responsible for the loading of the mRNA onto the ribosome, called synaptonemal complex protein 2 (SNCPT). SLCPT is a protein that plays a critical role in the regulation of mRNA stability and translation efficiency. It is known to interact with several other proteins, including SNORA19.

Several studies have shown that SNORA19 can interact with SLCPT and that this interaction may play a role in the regulation of gene expression. For example, one study published in the journal RNA Biology found that SNORA19 interacts with SLCPT and that this interaction is required for the proper function of SLCPT.

Another potential drug target based on SNORA19 is its role in the regulation of cell apoptosis, which is a natural process that helps the cell to eliminate damaged or dysfunctional parts. SNORA19 has been shown to play a role in the regulation of apoptosis in various cell types , including cancer cells.

One of the most promising potential drug targets based on SNORA19 is its role in the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can be treated with various drugs, including neurosteroids and neuroprotective agents. However, these treatments are often limited in their effectiveness and can have significant side effects.

Another potential drug target based on SNORA19 is its role in the regulation of cell signaling pathways. SNORA19 has been shown to interact with various signaling proteins, including the protein known as heat shock factor 1 (HSF1). HSF1 is a protein that plays a critical role in the regulation of cell signaling pathways and is known to interact with several other proteins, including SNORA19.

Finally, SNORA19 has also been shown to play a role in the regulation of cell cycle progression. The cell cycle is the process by which a cell grows and replicates its genetic material. SNORA19 has been shown to interact with the protein known as p21, which is a critical regulator of the cell cycle.

In conclusion, SNORA19 is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. Its functions have the potential to revolutionize our understanding of gene regulation and the development of new drugs. While more research is needed to fully determine its role, the potential targets based on SNORA19 are vast and continue to be an exciting area of 鈥嬧?媟esearch.

Protein Name: Small Nucleolar RNA, H/ACA Box 19

The "SNORA19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets